Bioventus (US:BVS)2025-05-06 13:27First Quarter 2025 Performance - Revenue was $124 million, a 4% decrease due to the divestiture of the Advanced Rehabilitation business[22] - Organic growth reached 5%, demonstrating solid performance across all three business segments[22] - Adjusted EPS increased 33% to $008[12] - Adjusted EBITDA was $19 million, a $3 million decrease compared to the prior year quarter, impacted by the Advanced Rehabilitation divestiture and a $11 million foreign currency loss[22] Segment Performance - Surgical Solutions revenue increased by 7%, driven by double-digit growth in Ultrasonics with U S capital sales up more than 50%[15,29] - Pain Treatments revenue increased by 4%, with growth impacted by a 3% to 4% reduction in distributor buying following higher purchases at the end of last year[26,29] - Restorative Therapies revenue declined by 35% due to the divestiture of the Advanced Rehabilitation business, while Exogen grew by 4%[28,29] Financial Guidance and Priorities - The company reaffirms its 2025 financial guidance, with net sales expected to be in the range of $560 million to $570 million, representing organic growth of 6% to 8%[40] - Adjusted EBITDA is projected to be in the range of $112 million to $116 million, and Adjusted Earnings Per Share is expected to be in the range of $064 to $068[40] - The company forecasts at least 100 basis points of Adjusted EBITDA margin expansion in 2025[17]